World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
152
Citations
115721
World Ranking
1061
National Ranking
609

Overview

Douglas Galasko is affiliated with the University of California, San Diego in the United States. Their research contributions focus primarily on the field of Medicine, with a significant emphasis on Neurology and related subfields.

The main areas of study for this scientist include:

  • Neurology
  • Psychiatry and Mental health
  • Physiology
  • Molecular Biology
  • Genetics

Douglas Galasko's work covers a range of topics related to neurological diseases, with a particular focus on neurodegenerative disorders. Their key research topics are:

  • Dementia and Cognitive Impairment Research
  • Alzheimer's disease research and treatments
  • Parkinson's Disease Mechanisms and Treatments
  • Neurological disorders and treatments
  • Neurological diseases and metabolism
  • Amyotrophic Lateral Sclerosis Research
  • Neuroinflammation and Neurodegeneration Mechanisms

The scientist has contributed to numerous publications in well-established venues, including:

  • Alzheimer s & Dementia
  • Neurology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Annals of Neurology
  • Journal of Alzheimer s Disease

Recent notable papers authored or coauthored include:

  • "Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group," 2021, The Lancet Neurology
  • "Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease," 2020, Nature
  • "Research criteria for the diagnosis of prodromal dementia with Lewy bodies," 2020, Neurology
  • "Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study," 2023, The Lancet Neurology
  • "Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study," 2020, Nature Communications

Douglas Galasko has frequently collaborated with several researchers, indicating a collaborative approach within their fields. Some of these frequent coauthors include:

  • Irene Litvan
  • David J. Irwin
  • Lawrence S. Honig
  • David P. Salmon
  • Bradley F. Boeve

Best Publications

  • Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

    I. G. McKeith;I. G. McKeith;D. W. Dickson;J. Lowe;M. Emre

  • Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

    Katya Rascovsky;John R. Hodges;David Knopman;Mario F. Mendez

  • Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

    Bruno Dubois;Howard H. Feldman;Claudia Jacova;Steven T. DeKosky

  • Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB international workshop

    I. G. Mckeith;D. Galasko;K. Kosaka;E. K. Perry

  • Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium

    Ian G. McKeith;Bradley F. Boeve;Dennis W. DIckson;Glenda Halliday

  • Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

    Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel

  • Revising the definition of Alzheimer's disease: a new lexicon.

    Bruno Dubois;Howard H. Feldman;Howard H. Feldman;Howard H. Feldman;Claudia Jacova;Jeffrey L. Cummings

  • Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

    Ronald C. Petersen;Ronald G. Thomas;Michael Grundman;David Bennett

  • Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

    Adam C. Naj;Gyungah Jun;Gary W. Beecham;Li-San Wang

  • The ageing systemic milieu negatively regulates neurogenesis and cognitive function

    Saul A. Villeda;Jian Luo;Kira I. Mosher;Bende Zou

  • The Parkinson Progression Marker Initiative (PPMI)

    Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  • Length of clinical trials of dementia drugs : Position paper from the international working group on harmonization of dementia drug guidelines

    Douglas Galasko;David Bennett;Mary Sano;Chris Ernesto

  • Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors

    Raj N. Kalaria;Gladys E. Maestre;Gladys E. Maestre;Raul Arizaga;Robert P. Friedland

  • Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

    Sandip Ray;Markus Britschgi;Charles Herbert;Yoshiko Takeda-Uchimura

  • Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

    Michael Grundman;Ronald C. Petersen;Steven H. Ferris;Ronald G. Thomas

  • The Lewy body variant of Alzheimer's disease A clinical and pathologic entity

    L. Hansen;D. Salmon;D. Galasko;E. Masliah

  • Rehabilitation of hemiparesis after stroke with a mirror.

    Eric Lewin Altschuler;Sidney B Wisdom;Lance Stone;Chris Foster

  • An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

    Galasko D;Bennett D;Sano M;Ernesto C

  • Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

    Ian G. McKeith

  • The Consortium to Establish a Registry for Alzheimer's Disease (CERAD).: Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years

    D. Galasko;S.D. Edland;J. C. Morris;C. Clark

Frequent Co-Authors

David P. Salmon
David P. Salmon University of California, San Diego
Elaine R. Peskind
Elaine R. Peskind University of Washington
Joseph F. Quinn
Joseph F. Quinn Oregon Health & Science University
Eliezer Masliah
Eliezer Masliah National Institutes of Health
James B. Leverenz
James B. Leverenz Cleveland Clinic
John Q. Trojanowski
John Q. Trojanowski University of Pennsylvania
Mark W. Bondi
Mark W. Bondi University of California, San Diego
Jeffrey Kaye
Jeffrey Kaye Oregon Health & Science University
Lawrence A. Hansen
Lawrence A. Hansen University of California, San Diego
John C. Morris
John C. Morris Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering Medicine in the USA, a variety of related online degrees and career pathways are available. With the evolving landscape of healthcare, many are opting for flexible learning programs that support their professional goals while accommodating busy schedules.

For those interested in mental health, several shortest online pmhnp programs allow you to earn credentials as a Psychiatric Mental Health Nurse Practitioner quickly and conveniently. Leadership-minded students may prefer healthcare administration degrees, which open doors to high-demand roles in healthcare management and policy.

Cost is another important factor. Prospective students can explore the cheapest mha online programs to gain vital skills for leadership positions, or consider the cheapest online bsn to dnp programs as a path to advanced nursing practice.

These diverse online options help you chart a personalized path in healthcare—whether in direct patient care, administration, or mental health specialties.

Best Scientists Citing Douglas Galasko

Trending Scientists